Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled dose-finding study of Jinghong Keli for stable angina due to coronary heart disease with qi deficiency and blood stasis syndrome
CTR20234195Phase 2Active
- Sponsor
- Xinjiang Institute of Materia Medica
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jinghong keli in coronary arteriosclerosis, angina pectoris, sponsored by Xinjiang Institute of Materia Medica. Started Dec 2023; status: active.
02
Drugs
jinghong keli
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on CTR20234195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234195.